Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2009 August;50(4) > The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

CASE REPORTS  VASCULAR SECTION


The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

language: English

Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection

Grubitzsch H. 1, Vargas-Hein O. 2, Von Heymann C. 2, Konertz W. 1

1 Department of Cardiovascular Surgery University of Clinic Charité Campus Charité Mitte, Berlin, Germany
2 Department of Anaesthesiology and Intensive Care Medicine University Clinic Charité Campus Charité Mitte, Berlin, Germany


PDF  


Despite appropriate treatment, surgery for aortic dissection is frequently associated with bleeding problems. In these series we report on the employment of recombinant activated factor VII (rFVIIa) for refractory hemorrhage after emergency surgery for acute type A aortic dissection, used to face the problems of postoperative blood loss and transfusion requirements. Despite the good results of the therapy, a patient presented with thrombosis of the left cavernous sinus. Although a risk of thromboembolic complications has to be considered, rFVIIa is a reasonable rescue option in life-threatening hemorrhage and enlarges our hemostatic armamentarium in surgery for acute aortic dissection.

top of page

Publication History

Cite this article as

Corresponding author e-mail